$434 Million is the total value of VHCP Management, LLC's 26 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SNSS | Exit | Sunesis Pharmaceuticals | $0 | – | -536,189 | -100.0% | -0.38% | – |
OHRP | Exit | OHR Pharmaceutical | $0 | – | -477,000 | -100.0% | -1.09% | – |
Exit | Radius Health Inc | $0 | – | -233,294 | -100.0% | -2.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
DBV Technologies | 14 | Q4 2016 | 33.5% |
BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
Lipocine Inc | 11 | Q4 2016 | 7.5% |
Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2018-02-28 |
13F-HR | 2017-02-13 |
13F-HR | 2016-11-14 |
13F-HR | 2016-08-12 |
13F-HR | 2016-05-13 |
13F-HR | 2016-02-12 |
13F-HR | 2015-11-13 |
13F-HR | 2015-08-13 |
3 | 2015-06-17 |
13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.